Gout treatment and pharmacogenetics
Also known as: Urate-lowering therapy, Hyperuricemia treatment
Why pharmacogenetics matter for gout treatment
Allopurinol is the workhorse of chronic gout treatment. The pharmacogenetic angle Gene2Rx covers is ABCG2: reduced-function carriers respond less to allopurinol and often need higher doses or a switch to febuxostat.[1] Patients of East Asian, South Asian, or African ancestry should also be aware that HLA-B*58:01 is a separate risk factor for severe allopurinol skin reactions. That allele isn't tested by Gene2Rx and is offered as a separate clinical test.[2]
ABCG2 reduced-function carriers often need higher allopurinol doses to reach the under-6 mg/dL urate target, or a switch to febuxostat.
Key gene in this class
Medications in this class covered by Gene2Rx
Explore each medication's genetic findings, supporting sources, and report information.
Brand products in the Gout meds class
Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.
References
- U.S. Food and Drug Administration. Table of Pharmacogenetic Associations (2024). fda.gov
- PharmGKB / Stanford University. PharmGKB: The Pharmacogenomics Knowledge Base. pharmgkb.org
Which gout meds is right for your genetics?
Informational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.